The orthopedic drug market is a highly competitive market and, in some areas, the competitive environment is being shaped by increasing levels of generic competition. Several large pharmaceutical companies compete in the orthopedic drug market, including Abbott, Eli Lilly, GlaxoSmithKline, Merck, Novartis, and Pfizer among others, and several other suppliers, such as Serono, NovoNordisk, Amgen, and Genentech are developing or offering products in more niche market areas.
For the purposes of this study, the world market for orthopedic drugs has been segmented in a few general treatment segments:
- Arthritis Treatments
- Osteoporosis, Paget’s Disease, and Other Bone Loss Treatments
- Growth Disorder Treatments
- Other Orthopedic Treatments
In each segment, the report discuses common orthopedic diseases and conditions in general and provides detailed information on individual diseases and conditions and treatment approaches. Each segment provides an overview, world and U.S. prevalence of the various conditions, a detailed description of products on the market, products in the research and development pipeline, and market estimates and forecasts by geographical region (U.S. vs non-U.S.) and by treatment type, including:
- NSAIDs and Cox-2 Inhibitors
- Antirheumatoids (DMARDS)
- SERMs
- Estrogen Combinations
- Bisphosphonates
- Calcitonins
- Polypeptide Hormones
- Sandostatin Analogs
- Skeletal Muscle Relaxants
- Pain Medications, and more
Competitive market share by leading supplier and leading drug are also provided in each segment, and the report reviews current business, regulatory, and clinical issues and trends affecting the industry and the direction of research and commercialization.
The research conducted by Kalorama Information included comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Person-to-person and telephone interviews were the primary method of gathering information. Interviews with over 75 key industry officials, consultants, health care providers, and government personnel were complied to form the primary basis of information - specifically the revenue and market share data - presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.
All market data pertain to the manufacturers’ level. The base year for data was 2005. Historical revenue data are provided for 2003 and 2004, with forecasts provided for 2006 through 2010. Market share information is provided for 2005. Compound annual growth rates (CAGRs) are provided for three periods in each industry segment: 2003-2005, 2005-2010, and 2003-2010.
Chapter one: Executive Summary
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting the Global Market
- Leading Competitors
Chapter Two: Introduction
- Structure and Function of Bone
- Structure and Function of Joints
- Structure and Function of Articular Cartilage
- Bone and Joint Trauma
- Demographics and Prevalence
chapter Three: Arthritis Treatments
- Description of Arthritic Conditions
- Ankylosing Spondylitis
- Juvenile Rheumatoid Arthritis
- Osteoarthritis
- Psoriatic Arthritis
- Reactive Arthritis
- Rheumatoid Arthritis
- Description of Products
- Nonsteriod Anti-Inflammatory Drugs/Cyclooxygenase-2 Inhibitors
- Disease Modifying Antirheumatoid Drugs
- Research and Development
- Areas and Directions
- Pipeline Products
- Arcoxia
- MabThera
- 406381
- Actemra
- Apilmod
- Cimzia (CDP 870)
- CNTO 148
- CTLA 41G
- D2E7 (Humira)
- Denosumab
- HCT 3012 (Naproxicinod)
- MRA
- Pennsaid
- Prexige
- Synvisc
- Market Size and Growth
- Market by Product Type
- Markets by Geographical Segments
- U.S. Market
- Non-U.S. Market
- Competitive Analysis
chapter Four: Bone Loss Treatments (Osteoporosis and Paget’s Disease)
- Description of Bone Conditions
- Osteoporosis
- Paget’s Disease
- Hypercalcemia
- Description of Products
- Bisphosphonates
- Calcitonins
- Estrogens and Combinations
- Selective Estrogen Receptor Modulators
- Other
- Research and Development
- Areas and Directions
- Pipeline Products
- Aclasta
- AMG 162
- Arzoxifene
- Banzedoxifene
- Denosumab
- Lasofoxifene (Oporia)
- Livial
- Oral Calcitonin
- Ostarine
- Preos
- S12911
- Market by Product Type
- Markets by Geographical Segments
- U.S. Market
- Non-U.S. Market
chapter Five: Growth Disorder Treatments
- Description of Growth Disorders
- Acromegaly
- Growth Hormone Deficiency
- Description of Products
- Polypeptide Hormones
- Somatostatin Analogs
- Research and Development
- Gentropin
- Omnitrope
- ALTU-238
- Market Size and Growth
- Market by Product Type
- Markets by Geographical Segment
- U.S. Market
- Non-U.S. Market
- Competitive Analysis
chapter Six: Other Orthopedic Treatments
- Description of Products
- Antibiotics
- Bone Cancer Drugs
- Bone Pain Drugs
- Skeletal Muscle Relaxants
- Research and Development
- Chrysalin
- Junovan
- OMS 103HP
- Market Size and Growth
- Market by Treatment Type
- Markets by Geographical Segments
- U.S. Market
- Non-U.S. Market
- Competitive Analysis
Chapter Seven: Issues and Trends Affecting the Orthopedic Drug Market
- New Therapies for Osteoporosis
- Osteobiologics
- Up-and-Coming Advances
- The Elderly
- Obesity
- Labeling
- FDA Actions
- Vitamin D and Black Women
- DTC Advertising
Chapter Eight: Orthopedic Drugs Market Size and Forecast Summary
- Overview
- Total Market Size and Forecast
- Markets by Therapeutic Segment
- Competitive Analysis
chapter Nine: Company Profiles
- Introduction
- Abbott Laboratories
- Amgen, Inc.
- Boehringer Ingelheim GmbH
- Chugai Pharmaceutical Company Ltd.
- Eli Lilly & Company
- Johnson & Johnson
- Merck & Company, Inc.
- Novartis International AG
- Novo Nordisk
- Pfizer, Inc.
- The Procter and Gamble Company
- Sanofi-Aventis
- Schering-Plough Corporation
- Wyeth
Appendix: Company Directory
List of Exhibits
Chapter one: Executive Summary
- Figure 1-1: Market Summary: World Market Orthopedic Drugs 2003-2010
- Table 1-2: Orthopedic Drugs: Leading Suppliers Significant Segments of Participation, 2005
Chapter Two: Introduction
- Table 2-1: Population by Country (Autralia, Canada, France, Germany, Italy, Japan, United Kingdom, United States) 2003-2010
- Figure 2-1: Population by Significant Market Country (Autralia, Canada, France, Germany, Italy, Japan, United Kingdom, United States) 2005 vs. 2010
- Table 2-2: Estimated World and U.S. Prevalence of Major Orthopedic Conditions
chapter Three: Arthritis Treatments
- Table 3-1: Estimated U.S. and World Prevalence of Arthritis Conditions (Ankylosing Spondylitis, Juvenile Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Reactive Arthritis, Rheumatoid Arthritis)
- Figure 3-1: Estimated World Prevalence of Arthritis Conditions
- Table 3-2: Products in Research and Development for Arthritis (Product, Developer, Indication, Development Phase/Status)
- Table 3-3: World Market Arthritis Treatments Total Revenues and Growth Rates 2003-2010
- Figure 3-2: Trending in the World Market Arthritis Treatments 2003-2010
- Table 3-4: World Market Arthritis Treatments Revenues and Growth Rates by Product Type (NSAIDS/Cox-2 vs. Antirheumatoids and Combinations) 2003-2010
- Figure 3-3: World Market Arthritis Treatments Trending by Product Type 2003-2010
- Table 3-5: World Market Arthritis Treatments by Geographical Segment (U.S. vs Non-U.S.) 2003-2010
- Figure 3-4: Trending in the World Market Arthritis Treatments by Geographical Segment 2003-2010
- Table 3-6: World Market Arthritis Treatments Revenues and Market Share by Leading Suppliers Estimated 2005 and Projected 2010
- Table 3-7: World Market Arthritis Treatments Estimated Sales and Market Share by Leading Product 2005
- Figure 3-5: Market Share of Top Arthritis Drugs 2005
chapter Four: Bone Loss Treatments (Osteoporosis and Paget’s Disease)
- Table 4-1: Estimated U.S. and World Prevalence of Bone Loss Conditions by Type (Osteoporosis, Paget’s Disease, Hypercalcemia, Low Bone Mass)
- Figure 4-1: Estimated World Prevalence of Bone Loss Conditions by Type (Osteoporosis, Paget’s Disease, and Other)
- Table 4-2: Products in Research and Development for Osteoporosis, Paget’s Disease and Other Bone Loss Disorders (Product, Developer, Development Phase/Status, Projected Approval Date)
- Table 4-3: World Market Bone Loss Treatments Total Revenues and Growth Rates 2003-2010
- Figure 4-2: Trending in the World Market Bone Loss Treatments 2003-2010
- Table 4-4: World Market Bone Loss Treatments by Product Type (SERMS & Estrogen Combinations, Bisphosphonates, Calcitonins) 2003-2010 Figure 4-3: Trending in the World Market Bone Loss Treatments by Product Type
- Table 4-5: World Market Bone Loss Treatments by Geographical Segment (U.S. vs Non-U.S.) 2003-2010
- Figure 4-4: Trending in the World Market Bone Loss Treatments by Geographical Segment 2003-2010
- Table 4-6: World Market Bone Loss Treatments Revenues and Market Share by Leading Suppliers Estimated 2005 and Projected 2010
- Table 4-7: World Market Bone Loss Treatments Estimated Sales and Market Share by Leading Product 2005
chapter Five: Growth Disorder Treatments
- Table 5-1: Estimated U.S. and World Prevalence of Growth Disorders by Type (Acromegaly, Pediatric GH Deficiency, Adult GH Deficiency)
- Figure 5-1: Estimated World Prevalence of Growth Disorders
- Table 5-2: Products in Research and Development for Growth Disorders (Product, Developer, Development Phase/Status, Projected Approval Date)
- Table 5-3: World Market for Growth Disorder Treatments Total Revenues and Growth Rates 2003-2010
- Figure 5-2: Trending in the World Market Growth Disorder Treatments, 2003-2010
- Table 5-4: World Market for Growth Disorder Treatments by Product Type (Polypeptide Hormones vs Sandostatin Analogs) 2003-2010
- Figure 5-3: Trending in the World Market for Growth Disorder Treatments by Product Type 2003-2010
- Table 5-5: World Market for Growth Disorder Treatments by Geographical Segment (U.S. vs Non-U.S.) 2003-2010
- Figure 5-4: Trending in the World Market for Growth Disorder Treatments by Geographical Segment 2003-2010
- Table 5-6: World Market Arthritis Treatments Revenues and Market Share by Leading Suppliers Estimated 2005 and Projected 2010
chapter Six: Other Orthopedic Treatments
- Table 6-1: Estimated U.S. and World Prevalence of Ankylosing Spondylitis, Juvenile Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Reactive Arthritis, and Rheumatoid Arthritis
- Figure 6-1: Estimated World Prevalence of Arthritis Conditions
- Table 6-2: Products in Research and Development for Other Orthopedic Indications (Product, Developer, Development Phase/Status, Indication, Projected Approval Date)
- Table 6-3: World Market for Other Orthopedic Treatments Total Revenues and Growth Rates 2003-2010
- Table 6-4: World Market for Other Orthopedic Treatments by Product Type (Pain Treatments, Muscle Relaxants, Others) 2003-2010
- Figure 6-2: Trending in the World Market for Other Orthopedic Treatments by Product Type 2003-2010
- Table 6-5: World Market for Other Orthopedic Treatments by Geographical Segment (U.S. vs Non-U.S.) 2003-2010
- Figure 6-3: Trending in the World Market for Other Orthopedic Treatments by Geographical Segment 2003-2010
Chapter Eight: Orthopedic Drugs Market Size and Forecast Summary
- Table 8-1: World Market for Orthopedic Drugs Total Revenues and Growth Rates 2003-2010
- Figure 8-1: Trending in the World Market Orthopedic Drugs, 2003-2010
- Table 8-2: World Market for Orthopedic Drugs by Therapeutic Segment 2003-2010
- Figure 8-2: Trending in the World Market for Orthopedic Drugs by Therapeutic Segment 2003-2010
- Figure 8-3: World Market for Orthopedic Drugs Revenue Distribution by Therapeutic Segment 2005
- Table 8-3: Orthopedic Drugs: Leading Suppliers Significant Segments of Participation, 2005
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook